title: Staging DLBCL: bone marrow biopsy or PET-CT?
abstract: In this issue of Blood, Khan and colleagues evaluated the clinical implications of marrow involvement identified by FDG-PET-CT (2-[¹⁸F]fluoro-2-deoxy-D-glucose-positron emission tomography combined with computed tomography) vs iliac crest biopsy in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). They showed that FDG-PET-CT scanning had a higher level of accuracy for identifying marrow disease than bone marrow (BM) biopsy (BMB). Nevertheless, the identification of BM involvement by histology per se still had a prognostic impact in terms of overall survival (OS) and progression-free survival (PFS).
authors.affiliation: The Chaim Sheba Medical Center, Tel Hashomer, Israel.
authors.forename: Abraham
authors.initials: A
authors.lastname: Avigdor
mesh_terms: D001853:Bone Marrow / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging*; D008297:Male; D064847:Multimodal Imaging / Q000379:methods*; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed